Department of Ophthalmology and Anatomy/Cell Biology
Wayne State University School of Medicine
Kresge Eye Institute
Specialty: Cataract, Dry Eye Disease, Comprehensive Ophthalmology
Medical School: Albert Einstein College of Medicine, Yeshiva University
Residency: Ophthalmology, Henry Ford Hospital, Detroit, Michigan
Fellowship: National Institutes of Health, Bethesda, MD
Appointment Locations: Bingham Farms and Detroit
Board Certification: American Board of Ophthalmology
Clinical Interests: Cataract surgery, dry eye diease, diabetic eye exams, macular degeneration, inflammatory eye diseases, glaucoma, external eye diseases
Research Interests: Developing thymosin beta 4 as a novel therapy for corneal wound healing, inflammation, and dry eye disease
Special Activities: Member, American Academy of Ophthalmology; Member, Association for Research in Vision and OphthalmologyHonors:
2011 AFER/Pfizer Ophthalmics Carl Camras Translational Research Award, ARVO, May 1, 2011, Fort Lauderdale, FL.
2012 Voted to Top Doctors Metro Detroit
2012 Top Ophthalmologist, International Association of Ophthalmologists
2013 Voted to Best Doctors of America
2014 Voted to Best Doctors of America
Sosne G, Ousler GW. Thymosin β4 Ophthalmic Solution for Dry Eye: A Randomized, Placebo-Controlled Phase 2 Clinical Trial Conducted Using the Controlled Adverse Environment (CAE™) Model. Expert Opinion. In revision.
Sosne G, Kim C, Kleinman HK. Thymosin β4 Significantly Reduces the Signs of Dry Eye in a Murine Controlled Adverse Environment Model of Experimental Dry Eye. Expert Opinion. In press.
Sosne G, Dunn SP, Kim C. Thymosin beta 4 Significantly Improve Signs and Symptoms of Severe Dry Eye in a Phase 2 Clinical Trial. CORNEA In press.
Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D. Thymosin β4: a potential novel dry eye therapy. Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x.
Goldstein, AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: A Multi-Functional Regenerative Peptide Basic Properties and Clinical Applications. Expert Opin Biol Ther. 2012 Jan;12(1):37-51. Epub 2011 Nov 10.
Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin beta 4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011 Feb 22, [Epub ahead of print]
Dunn SP, Heidemann DG, Chow CYC, Crockford D, Turjman N, Angel J, Allan CB, and Sosne G. “Treatment of Chronic Non-Healing Neurotrophic Corneal Epithelial Defects with Thymosin 4”
Ann N Y Acad Sci. 2010 Apr;1194:199-206. Dunn, SP, Heidemann DG, Chow CY, Crockford D, Turjman N,Angel, J, Allan CB, Sosne G. Arch Ophthalmol. Treatment of Chronic Nonhealing
Neurotrophic Corneal Epithelial Defects With Thymosin Beta 4. 2010 May; 128(5):636-8. Sosne G, Qiu P, Goldstein AL, Wheater MK. Biological activities of thymosin beta 4 defined by active sites in short peptide sequences. FASEB J. 2010 Jul;24(7):2144-51. Epub 2010 Feb 23. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal
NFkappaB: A potential anti-inflammatory pathway. Exp Eye Res. 2007 Apr;84(4):663-9. Gabriel Sosne, M.D.